SymphonyAI Acquires TeraRecon
|
By MedImaging International staff writers Posted on 01 Apr 2020 |
|
Illustration
SymphonyAI Group (Los Altos, CA, USA), an operating group of leading business-to-business artificial intelligence (AI) companies, has acquired TeraRecon (Durham, NC, USA), an advanced visualization and AI solution provider for medical imaging.
SymphonyAI Group focuses on delivering next-generation AI solutions for transforming the enterprise. SymphonyAI Group addresses use cases in healthcare and life sciences, retail and CPG, industrial manufacturing, energy, oil & gas, media and entertainment, defense, and financial services. TeraRecon offers medical advanced visualization and AI solutions and has developed sophisticated healthcare-focused AI platform solutions. Used by over 900 health systems globally, TeraRecon’s solutions provide radiologists and other highly specialized physicians with the software tools they need to quickly visualize and extract critical clinical data from medical images.
As SymphonyAI Group’s seventh portfolio company, TeraRecon has a charter to establish a new portfolio of healthcare AI solutions focused on medical imaging. Using its newly-patented AI and platform technology, TeraRecon will continue to focus on expanding its open platform for advanced visualization and AI-driven solutions. TeraRecon will accelerate the use of AI in other clinical specialties, including neurology and oncology, in addition to its market-leading solutions in radiology, cardiology, and vascular surgery.
SymphonyAI Group will invest in infrastructure and key initiatives to rapidly produce new advancements and offerings through TeraRecon’s industry-leading engineering and product teams. TeraRecon will operate as an independent portfolio company in the SymphonyAI Group. Synergies with TeraRecon technologies will complement the precision oncology offerings of portfolio company Concerto HealthAI.
“In just a few years, our company has not only transformed the realm of advanced visualization with artificial intelligence but also our entire industry,” said Jeff Sorenson, president and CEO of TeraRecon. “Now with the backing of SymphonyAI Group and the recent recognition of two powerful patents, TeraRecon can think bigger and work faster than ever before. Having been chosen for such an impressive and selective portfolio is truly an honor, and an ideal outcome for our employees, customers, and stockholders.”
“The SymphonyAI Group mission is to use AI to transform the enterprise. We accelerate high-value AI solutions to market to meet the needs of specific vertical industry use cases,” said Dr. Romesh Wadhwani, founder and CEO of SymphonyAI Group. “TeraRecon has demonstrated the value AI can play in the medical imaging market. We believe that TeraRecon AI technology can continue to deliver unprecedented benefits to doctors and patients and expand into new areas of the healthcare enterprise.”
“Artificial intelligence in medical imaging is expected to deliver several breakthroughs spanning a wide range of clinical areas and modalities,” said Vibhor Rastogi, investment partner at SymphonyAI Group. “With the acquisition of TeraRecon, SymphonyAI Group is bolstering its portfolio of AI-enabled enterprise solutions for the healthcare and life sciences industries. We are committed to leveraging AI to deliver breakthrough therapies and care delivery models.”
Related Links:
SymphonyAI Group
TeraRecon
SymphonyAI Group focuses on delivering next-generation AI solutions for transforming the enterprise. SymphonyAI Group addresses use cases in healthcare and life sciences, retail and CPG, industrial manufacturing, energy, oil & gas, media and entertainment, defense, and financial services. TeraRecon offers medical advanced visualization and AI solutions and has developed sophisticated healthcare-focused AI platform solutions. Used by over 900 health systems globally, TeraRecon’s solutions provide radiologists and other highly specialized physicians with the software tools they need to quickly visualize and extract critical clinical data from medical images.
As SymphonyAI Group’s seventh portfolio company, TeraRecon has a charter to establish a new portfolio of healthcare AI solutions focused on medical imaging. Using its newly-patented AI and platform technology, TeraRecon will continue to focus on expanding its open platform for advanced visualization and AI-driven solutions. TeraRecon will accelerate the use of AI in other clinical specialties, including neurology and oncology, in addition to its market-leading solutions in radiology, cardiology, and vascular surgery.
SymphonyAI Group will invest in infrastructure and key initiatives to rapidly produce new advancements and offerings through TeraRecon’s industry-leading engineering and product teams. TeraRecon will operate as an independent portfolio company in the SymphonyAI Group. Synergies with TeraRecon technologies will complement the precision oncology offerings of portfolio company Concerto HealthAI.
“In just a few years, our company has not only transformed the realm of advanced visualization with artificial intelligence but also our entire industry,” said Jeff Sorenson, president and CEO of TeraRecon. “Now with the backing of SymphonyAI Group and the recent recognition of two powerful patents, TeraRecon can think bigger and work faster than ever before. Having been chosen for such an impressive and selective portfolio is truly an honor, and an ideal outcome for our employees, customers, and stockholders.”
“The SymphonyAI Group mission is to use AI to transform the enterprise. We accelerate high-value AI solutions to market to meet the needs of specific vertical industry use cases,” said Dr. Romesh Wadhwani, founder and CEO of SymphonyAI Group. “TeraRecon has demonstrated the value AI can play in the medical imaging market. We believe that TeraRecon AI technology can continue to deliver unprecedented benefits to doctors and patients and expand into new areas of the healthcare enterprise.”
“Artificial intelligence in medical imaging is expected to deliver several breakthroughs spanning a wide range of clinical areas and modalities,” said Vibhor Rastogi, investment partner at SymphonyAI Group. “With the acquisition of TeraRecon, SymphonyAI Group is bolstering its portfolio of AI-enabled enterprise solutions for the healthcare and life sciences industries. We are committed to leveraging AI to deliver breakthrough therapies and care delivery models.”
Related Links:
SymphonyAI Group
TeraRecon
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
CT Phantom
CIRS Model 610 AAPM CT Performance Phantom
DR Flat Panel Detector
1500L
New
Breast Imaging Workstation
SecurView
Latest Industry News News
- Bayer and Google Partner on New AI Product for Radiologists
- Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
- IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering
- International Societies Suggest Key Considerations for AI Radiology Tools
- Samsung's X-Ray Devices to Be Powered by Lunit AI Solutions for Advanced Chest Screening
- Canon Medical and Olympus Collaborate on Endoscopic Ultrasound Systems
- GE HealthCare Acquires AI Imaging Analysis Company MIM Software
- First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors
- RSNA Unveils 10 Most Cited Radiology Studies of 2023
- RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More
- AI Medical Imaging Products to Increase Five-Fold by 2035, Finds Study
- RSNA 2023 Technical Exhibits to Highlight Latest Medical Imaging Innovations
- AI-Powered Technologies to Aid Interpretation of X-Ray and MRI Images for Improved Disease Diagnosis
- Hologic and Bayer Partner to Improve Mammography Imaging
- Global Fixed and Mobile C-Arms Market Driven by Increasing Surgical Procedures
- Global Contrast Enhanced Ultrasound Market Driven by Demand for Early Detection of Chronic Diseases
Channels
Radiography
view channel
Novel Breast Imaging System Proves As Effective As Mammography
Breast cancer remains the most frequently diagnosed cancer among women. It is projected that one in eight women will be diagnosed with breast cancer during her lifetime, and one in 42 women who turn 50... Read more
AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
Radiologists typically detect one case of cancer for every 200 mammograms reviewed. However, these evaluations often result in false positives, leading to unnecessary patient recalls for additional testing,... Read more
MRI
view channel
World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
MRI scanners are daily tools for doctors and healthcare professionals, providing unparalleled 3D imaging of the brain, vital organs, and soft tissues, far surpassing other imaging technologies in quality.... Read more
Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
Gadolinium, a heavy metal used for over three decades as a contrast agent in medical imaging, enhances the clarity of MRI scans by highlighting affected areas. Despite its utility, gadolinium not only... Read more.jpg "Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)")
Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read more
Ultrasound
view channel
Largest Model Trained On Echocardiography Images Assesses Heart Structure and Function
Foundation models represent an exciting frontier in generative artificial intelligence (AI), yet many lack the specialized medical data needed to make them applicable in healthcare settings.... Read more.jpg "Image: The Sonic Lumen Tomography (SLT) intravascular ultrasound system has received FDA 510(k) clearance (Photo courtesy of Provisio Medical)")
Groundbreaking Technology Enables Precise, Automatic Measurement of Peripheral Blood Vessels
The current standard of care of using angiographic information is often inadequate for accurately assessing vessel size in the estimated 20 million people in the U.S. who suffer from peripheral vascular disease.... Read more
Deep Learning Advances Super-Resolution Ultrasound Imaging
Ultrasound localization microscopy (ULM) is an advanced imaging technique that offers high-resolution visualization of microvascular structures. It employs microbubbles, FDA-approved contrast agents, injected... Read more
Novel Ultrasound-Launched Targeted Nanoparticle Eliminates Biofilm and Bacterial Infection
Biofilms, formed by bacteria aggregating into dense communities for protection against harsh environmental conditions, are a significant contributor to various infectious diseases. Biofilms frequently... Read moreNuclear Medicine
view channel
New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
Imaging inflammation using traditional radiological techniques presents significant challenges, including radiation exposure, poor image quality, high costs, and invasive procedures. Now, new contrast... Read more
New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more
New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
Ovarian cancer is the most lethal gynecological cancer, with less than a 30% five-year survival rate for those diagnosed in late stages. Despite surgery and platinum-based chemotherapy being the standard... Read more
AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read moreGeneral/Advanced Imaging
view channel
PET Scans Reveal Hidden Inflammation in Multiple Sclerosis Patients
A key challenge for clinicians treating patients with multiple sclerosis (MS) is that after a certain amount of time, they continue to worsen even though their MRIs show no change. A new study has now... Read more
Artificial Intelligence Evaluates Cardiovascular Risk from CT Scans
Chest computed tomography (CT) is a common diagnostic tool, with approximately 15 million scans conducted each year in the United States, though many are underutilized or not fully explored.... Read more
New AI Method Captures Uncertainty in Medical Images
In the field of biomedicine, segmentation is the process of annotating pixels from an important structure in medical images, such as organs or cells. Artificial Intelligence (AI) models are utilized to... Read more.jpg "Image: CT coronary angiography for diagnosing coronary artery disease offers advantages over other diagnostic tests (Photo courtesy of 123RF)")
CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
Coronary artery disease (CAD), one of the leading causes of death worldwide, involves the narrowing of coronary arteries due to atherosclerosis, resulting in insufficient blood flow to the heart muscle.... Read moreImaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
